The Trump administration on Tuesday announced the 15 drugs selected to participate in the newest round of the Medicare Drug ...

Lower prices from the third round of talks among Medicare and manufacturers will be announced in the fall but won’t go into ...

The Centers for Medicare and Medicaid Services has announced the selection of 15 prescription drugs for the third cycle of ...

The Trump administration has unveiled 15 new drugs selected for a Medicare drug price negotiation program that allows the ...

HealthDay News — Fifteen prescription medications, including Botox and the diabetes drug Trulicity, will be the focus of ...

Medicare selects Botox and Trulicity among 15 high-cost drugs for price negotiations under new federal authority, with lower ...

About 1.8 million people used one or more of the 15 drugs through Medicare Part D or Part B between November 2024 and October 2025, the CMS said. The batch of 15 meds accounted for about $27 billion ...

The Trump administration released the next 15 drugs subject to Medicare price negotiation, including for the first time ...

Still, the medications in the latest round of negotiations — which now includes “Part B” drugs given in doctors offices — ...

CMS's third drug negotiation cycle under the IRA targets high-expenditure drugs, impacting Medicare Part B and D spending. The list includes drugs for cancer, HIV, and diabetes, with significant ...